-
Pols DHJ, Nielen Mark MJ, Korevaar JC, et al. Reliably estimating prevalences of atopic children: an epidemiological study in an extensive and representative primary care database. NPJ Prim Care Respir Med 2017;27.
-
Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733-743.
-
-
Linna O, Kokkonen J, Lathela P, et al. Ten-year prognosis for generalized infantile eczema. Acta Paediatr 1992;81:1013-1016.
-
Dirven-Meijer PC, De Kock CA, Nonneman MMG, et al. NHG-Standaard Eczeem. 2014. Geraadpleegd juli 2021
-
Schultz Larsen FV, Holm NV. Atopic dermatitis in a population based twin series. Concordance rates and heritability estimation. Acta Derm Venereol Suppl 1985;114:159.
-
Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007;156:203-21.
-
Cookson WO, Moffatt MF. The genetics of atopic dermatitis. Curr Opin Allergy Clin Immunol 2002;2:383-7.
-
Williams HC. On the definition and epidemiology of atopic dermatitis. Dermatol Clin 1995;13:649-657.
-
Thijs JT, Damoiseaux RAMJ, Lucassen P, et al. Allergologisch onderzoek bij constitutioneel eczeem: vaak niet nodig [Allergy testing in atopic dermatitis: often unnecessary]. Ned Tijdschr Geneeskd 2013;157(12):A5652.
-
Feinberg J. The effect of patient-practitioner interaction on compliance: a review of the literature and application in rheumatoidarthritis. Pat Educ Couns 1988;11:171-87.
-
Eraker SA, Kirscht JP, Becker MH. Understanding and improving compliance. Ann Intern Med 1984;100:258-68.
-
Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medicationcompliance. Arch Intern Med 1990;150:1881-4.
-
Roth HP, Caron HS. Accuracy of doctors‘ statements on adherence to a drug regimen. Clin Pharmacol Ther 1978;23:361-70.
-
KNMP. Informatorium Medicamentorum 2013. Geraadpleegd maart 2019.
-
-
-
Chi CC, et al. Evidence-based (S3) guideline on topical corticosteroïds in pregnancy. Br J Dermatol 2011;165:943-52.
-
Chi CC, et al. Pregnancy outcomes after maternal exposure to topical corticosteroïds-a UK population-based cohort study. JAMA Dermatol 2013;149:1274-80.
-
Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011;165:808-14.
-
Stewart S, Pasmans S, De Bruin-Weller M. Dermatocorticosteroïden bij constitutioneel eczeem. Huisarts en Wetenschap 2013.
-
Finlay AY, Edwards PH, Harding KG. “Fingertip unit” in dermatology. Lancet 1989;8655:155.
-
Long CC, Finlay AY. The rule of hand: 4 hand areas=2 FTU=1g. Arch Dermatol 1992;128:1129-30.
-
Green C, Colquitt JL, Kirby J, et al. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005;152:130-41.
-
Hoare C, Li Wan PA, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191.
-
Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998;139:763-6.
-
Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Br Med J 2003;326:1367.
-
Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-37.
-
Schmitt J, Kobyletzki von L, Svensson A, et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011;164(2):415-28.
-
NHG. Richtlijn Informatie-uitwisseling tussen huisarts en medisch-specialist (HASP). Federatie Medisch Specialisten. 2017.
-
Schuttelaar ML, De Bruin-Weller MS, Oosting B, et al. Introductie van dupilumab voor ernstig constitutioneel eczeem (CE). Standpunt Nederlandse Vereniging voor dermatologie en venereologie. 2018.
-
-
De Wijs LEM, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol 2020;182(2):418-426.
-
De Wijs LEM, Hijnen D.J. Eerste ervaringen met dupilumab in de dagelijkse praktijk. NTvDV 2018;28(10):35-37.
-
Account
1
